Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 1, 2014, Pages 15-23

  Solomon, B ^a   Wilner, K D ^b   Shaw, A T ^c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PFIZER INC   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP26113; ASP3026; CRIZOTINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; LDK378; MICROTUBULE ASSOCIATED PROTEIN 4; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RECEPTOR TYROSINE KINASE 1; RECEPTOR TYROSINE KINASE 2; RO5424802; STAT3 PROTEIN; STAT5 PROTEIN; TSR 011; UNCLASSIFIED DRUG; X 396;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; GENE REARRANGEMENT; HUMAN; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84890929261     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.200     Document Type: Article

References (96)

1. Morris, S.W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994). (Pubitemid 24107549)
2. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall- cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
3. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007). (Pubitemid 350235027)
4. Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 8, 11-23 (2008).
5. Englund, C. et al. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 425, 512-516 (2003). (Pubitemid 37237046)
6. Lee, H.H., Norris, A., Weiss, J.B. & Frasch, M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 425, 507-512 (2003). (Pubitemid 37237045)
7. Reiner, D.J., Ailion, M., Thomas, J.H. & Meyer, B.J. C. elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-beta signaling. Curr. Biol. 18, 1101-1109 (2008).
8. Bilsland, J.G. et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 33, 685-700 (2008).
9. Griffin, C.A., Hawkins, A.L., Dvorak, C., Henkle, C., Ellingham, T. & Perlman, E.J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2776-2780 (1999). (Pubitemid 29283106)
10. Debelenko, L.V. et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod. Pathol. 24, 430-442 (2011).
11. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
12. Lin, E. et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol. Cancer Res. 7, 1466-1476 (2009).
13. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
14. George, R.E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
15. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
16. Mossé, Y.P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
17. Murugan, A.K. & Xing, M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71, 4403-4411 (2011).
18. Soda, M. et al. A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. USA 105, 19893-19897 (2008).
19. Sharma, S.V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 (2007). (Pubitemid 350277749)
20. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALKrearranged lung Cancers. Sci. Transl. Med. 4, 120ra17 (2012).
21. Ou, S.H., Bartlett, C.H., Mino-Kenudson, M., Cui, J. & Iafrate, A.J. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17, 1351-1375 (2012).
22. Majewski, I.J. et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J. Pathol. 230, 270-276 (2013).
23. Heuckmann, J.M. et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin. Cancer Res. 18, 4682-4690 (2012).
24. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
25. Solomon, B., Varella-Garcia, M. & Camidge, D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 4, 1450-1454 (2009).
26. Rodig, S.J. et al. Unique clinicopathologic features characterize ALKrearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15, 5216-5223 (2009).
27. Yoshida, A. et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am. J. Surg. Pathol. 35, 1226-1234 (2011).
28. Zhang, Y.G. et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS ONE 8, e64821 (2013).
29. Shaw, A.T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
30. Camidge, D.R. et al. Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011-1019 (2012).
31. Shaw, A.T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
32. Shaw, A.T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
33. Wong, D.W. et al.; University of Hong Kong Lung Cancer Study Group. The EML4- ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115, 1723-1733 (2009).
34. Paik, J.H. et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J. Thorac. Oncol. 6, 466-472 (2011).
35. Gainor, J.F. et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res. 19, 4273-4281 (2013).
36. Johnson, B.E., Kris, M.G. & Lynne, D.B. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J. Clin. Oncol. 31 (suppl.; abstr. 8019) (2013).
37. Wu, S.G. et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J. Thorac. Oncol. 7, 98-104 (2012).
38. Yang, P. et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J. Thorac. Oncol. 7, 90-97 (2012).
39. Doebele, R.C. et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 118, 4502-4511 (2012).
40. Hanna, N. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004). (Pubitemid 41079796)
41. Camidge, D.R. et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol. 6, 774-780 (2011).
42. Shaw, A.T. et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann. Oncol. 24, 59-66 (2013).
43. Lee, J.K. et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 118, 3579-3586 (2012).
44. Kim, H.R. et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 118, 729-739 (2012).
45. Shaw, A.T., Solomon, B. & Kenudson, M.M. Crizotinib and testing for ALK. J. Natl. Compr. Canc. Netw. 9, 1335-1341 (2011).
46. Kim, H. et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J. Thorac. Oncol. 6, 1359-1366 (2011).
47. Yi, E.S., Chung, J.H., Kulig, K. & Kerr, K.M. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. Mol. Diagn. Ther. 16, 143-150 (2012).
48. Yi, E.S. et al. Correlation of IHC and FISH for ALK gene rearrangement in nonsmall cell lung carcinoma: IHC score algorithm for FISH. J. Thorac. Oncol. 6, 459-465 (2011).
49. Selinger, C.I. et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. (2013) 2013 Jun 7. doi: 10.1038/ modpathol.2013.87. [Epub ahead of print].
50. Sakai, Y. et al. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung. Int. J. Surg. Pathol. 21, 476-482 (2013).
51. Park, H.S. et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77, 288-292 (2012).
52. Martinez, P. et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS ONE 8, e52261 (2013).
53. Conklin, C.M., Craddock, K.J., Have, C., Laskin, J., Couture, C. & Ionescu, D.N. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J. Thorac. Oncol. 8, 45-51 (2013).
54. Boland, J.M. et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum. Pathol. 40, 1152-1158 (2009).
55. Pailler, E. et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J. Clin. Oncol. 31, 2273-2281 (2013).
56. Jung, Y. et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes. Chromosomes Cancer 51, 590-597 (2012).
57. Ou, S.H. et al. Activity of crizotinib (PF02341066), a dual mesenchymalepithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
58. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
59. XALKORI [package insert], Pfizer:US, 2013.
60. Kim, D.K. et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30, (suppl; abstr. 7533) (2012).
61. Ou, S.H. et al. Efficacy and safety of crizotinib in patients with advanced ROS1- rearranged non-small cell lung cancer (NSCLC). J. Clin. Oncol. 31 (suppl.; abstr. 8032) (2013).
62. Chu, A.S. et al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. J. Clin. Oncol. 29 (suppl.; abstr. 2072) (2012).
63. Lennerz, J.K. et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011).
64. Butrynski, J.E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727-1733 (2010).
65. Stasia, A. et al. Crizotinib obtains durable responses in advanced chemoresistant ALK+ lymphoma patients. Haematologica 97 (suppl. 1), 488 (2012).
66. Mossé, Y.P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472-480 (2013).
67. Ou, S.H., Tong, W.P., Azada, M., Siwak-Tapp, C., Dy, J. & Stiber, J.A. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 119, 1969-1975 (2013).
68. Weickhardt, A.J. et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 118, 5302-5309 (2012).
69. Li, C., Alvey, C., Bello, A., Wilner, K. & Tan, W. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J. Clin. Oncol. 29 (suppl.; abstr. e13065) (2011).
70. Choi, Y.L. et al.; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010).
71. Doebele, R.C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012).
72. Sasaki, T. et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71, 6051-6060 (2011).
73. Huang, D. et al. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics 102, 157-162 (2013).
74. Kim, S. et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J. Thorac. Oncol. 8, 415-422 (2013).
75. Weickhardt, A.J. et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30 (suppl.; abstr. 7526) (2012).
76. Costa, D.B. et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 29, e443-e445 (2011).
77. Marsilje, T.H. et al. Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4- (2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials. J. Med. Chem. (2013).
78. Galkin, A.V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 104, 270-275 (2007). (Pubitemid 46068021)
79. Shaw, A.T. & Engelman, J.A. ALK in lung cancer: past, present, and future. J. Clin. Oncol. 31, 1105-1111 (2013).
80. Sakamoto, H. et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679-690 (2011).
81. Kinoshita, K. et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg. Med. Chem. 20, 1271-1280 (2012).
82. Seto, T. et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, openlabel, phase 1-2 study. Lancet Oncol. 14, 590-598 (2013).
83. Zhang, S. et al. Proceedings: AACR 101st Annual Meeting 2010, 15 April 2010. Cancer Res. 70 (8; 70 suppl. 1; abstr. LB-298) (2010).
84. Rivera, V.M. et al. AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC Proceedings: AACR 103rd Annual Meeting, AACR 2012, Chicago, USA, 2 April, 2012 (2012).
85. Camidge, D.R. et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. J. Clin. Oncol. 31 (suppl.; abstr. 8031) (2013).
86. Lovly, C.M. et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 71, 4920-4931 (2011).
87. Kuromitsu, S. et al. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, 12-16 November 2011. Mol. Cancer. Ther. 10 (suppl. 11; abstr. nr A227) (2011).
88. Patnaik, A. et al. Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial. J. Clin. Oncol. 31 (suppl.; abstr. 2602) (2013).
89. Wilcoxen, K.M. et al. Proceedings of AACR, 15 April 2012. Cancer Res. 71 (8; suppl. 1; abstr. 1795) (2012).
90. Bonvini, P., Gastaldi, T., Falini, B. & Rosolen, A. Nucleophosminanaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin. Cancer Res. 62, 1559-1566 (2002). (Pubitemid 34407823)
91. Katayama, R. et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. USA 108, 7535-7540 (2011).
92. Normant, E. et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30, 2581-2586 (2011).
93. Sang, J. et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 3, 430-443 (2013).
94. Sequist, L.V. et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol. 28, 4953-4960 (2010).
95. Socinski, M.A. et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin. Cancer Res. 19, 3068-3077 (2013).
96. Felip, E. et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer. Ann. Oncol. 23, ix152; abstr. 4380 (2012).